These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19688063)

  • 1. Intestinal perforation in colorectal cancers treated with bevacizumab (Avastin).
    Choi YI; Lee SH; Ahn BK; Baek SU; Park SJ; Kim YS; Shin SH
    Cancer Res Treat; 2008 Mar; 40(1):33-5. PubMed ID: 19688063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery].
    Abbrederis K; Kremer M; Schuhmacher C
    Chirurg; 2008 Apr; 79(4):351-5. PubMed ID: 17453167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When a good call leads to a bad connection: colovesical fistula in colorectal cancer treated with bevacizumab.
    Chen J; Smalligan RD; Nadesan S
    Hosp Pract (1995); 2016 Aug; 44(3):120-2. PubMed ID: 27309405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Two Cases of Bowel Perforation during Chemotherapy with Bevacizumab to Metastatic Rectal Cancer].
    Miyake Y; Ikeda K; Murakami M; Oka Y; Nezu R; Kurokawa E; Kikkawa N
    Gan To Kagaku Ryoho; 2015 Dec; 42 Suppl 1():75-8. PubMed ID: 26809419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
    Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
    Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report of perforation of an ileal neobladder after treatment of rectal cancer with bevacizumab and comment on mechanisms of intestinal perforation associated with bevacizumab.
    Liu SV; Gollard R; Iqbal S
    J Clin Pharm Ther; 2012 Oct; 37(5):607-9. PubMed ID: 22432770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
    August DA; Serrano D; Poplin E
    J Surg Oncol; 2008 Feb; 97(2):180-5. PubMed ID: 18095268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal Perforation With an Intraluminal Stent and Bevacizumab use in Advanced Metastatic Colorectal Cancer.
    Akeel N; Toonsi WA
    Cureus; 2021 Jan; 13(1):e12831. PubMed ID: 33628692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice.
    Prescrire Int; 2006 Jun; 15(83):94-7. PubMed ID: 16764097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
    Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
    Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
    Heinzerling JH; Huerta S
    Curr Surg; 2006; 63(5):334-7. PubMed ID: 16971205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of severe bevacizumab-induced ischemic pancolitis, treated with conservative management].
    Lee HN; Lee MA; Kim SW; Lim Y; Lee H; Lee HM; Won HS; Chun SH
    Korean J Gastroenterol; 2011 Jul; 58(1):42-6. PubMed ID: 21778803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.
    Kwon HC; Oh SY; Lee S; Kim SH; Kim HJ
    World J Gastroenterol; 2007 Dec; 13(46):6231-5. PubMed ID: 18069765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A Case of Duodenal Perforation during Bevacizumab Combination Chemotherapy in a Patient with Multiple Lung Metastasis after a Sigmoidectomy].
    Suzumura H; Shinozaki H; Kondo R; Yamaguchi M; Torizaki Y; Ozawa Y; Futoh Y; Matsuoka T; Matsumoto K; Inoue M; Sasakura Y; Terauchi T; Kimata M; Furukawa J; Kobayashi K; Ogata Y
    Gan To Kagaku Ryoho; 2019 May; 46(5):953-955. PubMed ID: 31189824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab: a review of its use in metastatic colorectal cancer.
    McCormack PL; Keam SJ
    Drugs; 2008; 68(4):487-506. PubMed ID: 18318567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on bevacizumab in metastatic colorectal cancer.
    McCormack PL; Keam SJ
    BioDrugs; 2008; 22(5):339-41. PubMed ID: 18778115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.
    Roohullah A; Wong HL; Sjoquist KM; Gibbs P; Field K; Tran B; Shapiro J; Mckendrick J; Yip D; Nott L; Gebski V; Ng W; Chua W; Price T; Tebbutt N; Chantrill L
    World J Gastroenterol; 2015 May; 21(17):5352-8. PubMed ID: 25954110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
    Bennouna J; Sastre J; Arnold D; Österlund P; Greil R; Van Cutsem E; von Moos R; Viéitez JM; Bouché O; Borg C; Steffens CC; Alonso-Orduña V; Schlichting C; Reyes-Rivera I; Bendahmane B; André T; Kubicka S;
    Lancet Oncol; 2013 Jan; 14(1):29-37. PubMed ID: 23168366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of chemotherapy and targeted antiVEGF- and antiEGFR-therapy in metastatic colorectal cancer: a case report of long-term and intensive response].
    Nemecek R; Vyzula R
    Klin Onkol; 2011; 24(6):465-9. PubMed ID: 22257237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.